Skip to main content
Fig. 2 | BMC Nephrology

Fig. 2

From: Monthly mini-dose rituximab for primary anti-PLA2R-positive membranous nephropathy: a personalized approach

Fig. 2

Immunological changes in individual patients before and after monthly mini-dose rituximab treatment. A. CD19 + B lymphocyte count; B. CD20 + B lymphocyte count; C. Anti-phospholipase A2 receptor antibody titer; D. Circulating peak and trough rituximab concentration(Peak: samples were obtained the next morning after rituximab infusion; trough: samples were acquired a couple of days before the next rituximab treatment)

Back to article page

BMC Nephrology

ISSN: 1471-2369

Contact us